Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass.

Albumin versus various colloids including several HES preparations has been evaluated in many recent trials in cardiopulmonary bypass. This trial, reporting no difference between albumin and HES 130/0.4 on coagulation variables, blood loss and immunological activity does not add any new information to the body of evidence already present in the area.

– Kathrine Holte